Search research articles
Contact Us
Filters
Showing results (331-340 of 493) with videos related to
Page
of 50
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology
|
May 14, 2005
GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta
James L Park, Robert D Loberg, Damon Duquaine, et al.
Oncotarget
|
June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
Xiaoen Wang, Nicolas Solban, Prateek Khanna, et al.
ESMO Open
|
February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>
A A Tarhini, K Toor, K Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Ravi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Oncotarget
|
February 4, 2017
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma
Cynthia M Simbulan-Rosenthal, Sivanesan Dakshanamurthy, Anirudh Gaur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu, Maneka Puligandla, Judith Manola, et al.
ESMO Open
|
April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
J B A G Haanen, J Larkin, T K Choueiri, et al.
Journal of the Endocrine Society
|
December 8, 2025
Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response
Leila Shobab, Jennifer Simpson, Matthew McCoy, et al.
Plos One
|
May 12, 2011
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Page
of 50
Search research articles
Search
Showing results (331-340 of 493) with videos related to
Sort By:
Page
of 50
Arteriosclerosis, Thrombosis, and Vascular Biology
|
May 14, 2005
GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta
James L Park, Robert D Loberg, Damon Duquaine, et al.
Oncotarget
|
June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
Xiaoen Wang, Nicolas Solban, Prateek Khanna, et al.
ESMO Open
|
February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>
A A Tarhini, K Toor, K Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Ravi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Oncotarget
|
February 4, 2017
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma
Cynthia M Simbulan-Rosenthal, Sivanesan Dakshanamurthy, Anirudh Gaur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu, Maneka Puligandla, Judith Manola, et al.
ESMO Open
|
April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
J B A G Haanen, J Larkin, T K Choueiri, et al.
Journal of the Endocrine Society
|
December 8, 2025
Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response
Leila Shobab, Jennifer Simpson, Matthew McCoy, et al.
Plos One
|
May 12, 2011
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Page
of 50